Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04632108 is registered in ClinicalTrials.gov with Jiangsu Aosaikang Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04632108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04632108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 28, 2021
Completion date
December 31, 2025
Enrollment
199 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumor